| Pharmaceutical Information |
| Drug Name |
Iobenguane i-123 |
| Drug ID |
BADD_D01173 |
| Description |
Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline. Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008. |
| Indications and Usage |
Detection of primary and metastatic pheochromocytoma or neuroblastoma |
| Marketing Status |
approved; investigational |
| ATC Code |
V09IX02 |
| DrugBank ID |
DB06704
|
| KEGG ID |
Not Available
|
| MeSH ID |
D019797
|
| PubChem ID |
135326
|
| TTD Drug ID |
D02JIS
|
| NDC Product Code |
17156-235 |
| UNII |
P2TH1XYZ84
|
| Synonyms |
3-Iodobenzylguanidine | 3 Iodobenzylguanidine | MIBG | meta-Iodobenzylguanidine | meta Iodobenzylguanidine | Iobenguane | m-Iodobenzylguanidine | m Iodobenzylguanidine | Iobenguane (131I) | 3-Iodobenzylguanidine, 125I Labeled | 125I Labeled 3-Iodobenzylguanidine | 3 Iodobenzylguanidine, 125I Labeled | (3-Iodo-(131I)benzyl)guanidine | 3-Iodobenzylguanidine, 123I Labeled | 123I Labeled 3-Iodobenzylguanidine | 3 Iodobenzylguanidine, 123I Labeled |
|
| Chemical Information |
| Molecular Formula |
C8H10IN3 |
| CAS Registry Number |
76924-93-1 |
| SMILES |
C1=CC(=CC(=C1)I)CN=C(N)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
